| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $762K | — | -41.6% |
| SG&A Expense | $1.3M | — | -28.1% |
| Operating Income | -$2.0M | — | +33.8% |
| Net Income | -$2.1M | — | +25.7% |
| EPS (Basic) | -$0.19 | — | +57.8% |
| EPS (Diluted) | -$0.19 | — | +57.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15K | -48.3% | -99.1% |
| Current Assets | $184K | -40.1% | -92.1% |
| Total Assets | $755K | -26.1% | -78.9% |
| Current Liabilities | $11.8M | +6.9% | +7.9% |
| Total Liabilities | $11.8M | +6.9% | +6.7% |
| Stockholders' Equity | -$11.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.3M | — | +19.1% |
| Financing Cash Flow | $1.3M | — | -59.5% |
| -47.6% |